« Back

Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program

03/20/18 8:30 AM EDT

-- The Company will award 10 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy --

CAMBRIDGE, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today the launch of its Route 79, The Duchenne Scholarship Program, an annual scholarship for students diagnosed with Duchenne muscular dystrophy (DMD). The Route 79 program is designed to help students with DMD pursue their post-secondary educational goals. Scholarships of up to $10,000 will be awarded to 10 individuals chosen by an independent committee of DMD community members based on an applicant’s community involvement and a personal essayi.

“We are pleased to announce the launch of our Route 79, The Duchenne Scholarship Program,” said Douglas Ingram, Sarepta’s president and chief executive officer. “The road traveled by each individual with DMD is distinct. We are honored to help empower the educational goals of those DMD students who have chosen higher education; and we are excited to follow the achievements and societal contributions these remarkable individuals can make in the future.”

The underlying cause of DMD is a mutation or error in the gene coding for dystrophin. Dystrophin is an essential protein that plays a pivotal role in muscle structure, function and preservation. The numerical significance of the scholarship’s name, Route 79, ties to the 79 exons of the dystrophin gene.

To apply for a scholarship through the Route 79 program, applicants must be either a high school senior or a college freshman, sophomore or junior in good academic standing, accepted to or enrolled into an accredited college or university or a trade, technical or vocational school located in the United States and be diagnosed with DMD.

Applications will be accepted until May 31, 2018 at 11:59 PM PT. Recipients will be announced in July 2018 and awards will be distributed by mid-August, in time for fall 2018 enrollment. Students may apply by clicking here.

About Sarepta Therapeutics

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.

Source: Sarepta Therapeutics, Inc.

Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
W2O Group
Brian Reid, 212-257-6725

i No consideration will be given to whether or not an applicant was previously, is currently, or expects to be in the future, undergoing treatment with a Sarepta product or investigational product.


Primary Logo


Source: Sarepta Therapeutics, Inc.



This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.